NMT Medical Announces Favorable Nasdaq National Market Continued Listing Determination

Apr 19, 2001, 01:00 ET from NMT Medical, Inc.

    BOSTON, April 19 /PRNewswire/ -- NMT Medical, Inc. (Nasdaq: NMTI)
 announced today that it recently received notice from the Nasdaq National
 Market (the "NNM") that the Nasdaq Listing Qualifications Panel (the "Panel")
 of the NNM had determined to continue the listing of the Company's common
 stock on the NNM.  This notice follows a hearing before the Panel held on
 March 22, 2001 where representatives of the Company presented evidence
 relating to the Company's ongoing ability to meet the NNM's continued listing
 requirements, including the maintenance of net tangible assets equal to at
 least $4 million.
     The Company is obligated to timely file its Quarterly Report on Form 10-Q
 relating to the quarter ended March 31, 2001 with the SEC and Nasdaq, and
 until this filing, provide the Panel prompt notification of any significant
 events involving the Company.  The Nasdaq Marketplace Rules provide that the
 Nasdaq Listing and Hearing Review Council (the "Council") may, on its own
 motion, determine to review this Panel decision at any time until
 May 28, 2001.  In the event of such a review, there can be no assurance that
 the Council will affirm the Panel's determination relating to the Company's
 continued listing on the NNM.
     Commenting on the Panel's decision, John E. Ahern, the Company's President
 and Chief Executive Officer, stated that, "We are very pleased that the Panel
 agreed with our assessment of the Company's financial health and its ability
 to meet the NNM's continued listing requirements.  The entire NMT management
 team is committed to continue our operating momentum and to take the steps
 necessary to keep NMT listed on the NNM."
     NMT Medical designs, develops and markets innovative medical devices that
 utilize advanced technologies and are delivered by minimally invasive
 procedures.  The Company's products are designed to offer alternative
 approaches to existing complex treatments, thereby reducing patient trauma,
 shortening procedure, hospitalization and recovery times, and lowering overall
 treatment costs.  The Company's cardiovascular business unit provides the
 interventional cardiologist, interventional radiologist, and vascular surgeon
 with proprietary catheter-based implant technologies that minimize or prevent
 the risk of embolic events.  The cardiovascular business unit also serves the
 pediatric interventional cardiologist with a broad range of cardiac septal
 repair implants delivered with nonsurgical catheter techniques.  The NMT
 neurosciences business unit serves the needs of neurosurgeons with a range of
 implantable and single-use products, including cerebral spinal fluid shunts,
 external drainage products, and the Spetzler(TM) Titanium Aneurysm Clip.
     This press release contains "forward-looking statements" within the
 meaning of the Private Securities Litigation Reform Act of 1995.  Such
 forward-looking statements, including statements regarding the potential of
 the Company's CardioSEAL technology in treating PFOs, involve known and
 unknown risks, uncertainties or other factors which may cause actual results,
 performance or achievements of the Company to be materially different from any
 future results, performance or achievements expressed or implied by such
 forward-looking statements.  Factors that might cause such a difference
 include, but are not limited to, those discussed under the heading "Certain
 Factors That May Affect Future Results" included in the Management's
 Discussion and Analysis of Financial Condition and Results of Operations in
 the Company's Annual Report on Form 10-K for the year ended December 31, 2000
 and subsequent filings with the Securities and Exchange Commission.
     To receive NMT Medical's latest news release and other corporate documents
 via FAX -- at no cost -- please dial 1-800-PRO-INFO.  Enter the Company's
 symbol NMTI.
 
 

SOURCE NMT Medical, Inc.
    BOSTON, April 19 /PRNewswire/ -- NMT Medical, Inc. (Nasdaq: NMTI)
 announced today that it recently received notice from the Nasdaq National
 Market (the "NNM") that the Nasdaq Listing Qualifications Panel (the "Panel")
 of the NNM had determined to continue the listing of the Company's common
 stock on the NNM.  This notice follows a hearing before the Panel held on
 March 22, 2001 where representatives of the Company presented evidence
 relating to the Company's ongoing ability to meet the NNM's continued listing
 requirements, including the maintenance of net tangible assets equal to at
 least $4 million.
     The Company is obligated to timely file its Quarterly Report on Form 10-Q
 relating to the quarter ended March 31, 2001 with the SEC and Nasdaq, and
 until this filing, provide the Panel prompt notification of any significant
 events involving the Company.  The Nasdaq Marketplace Rules provide that the
 Nasdaq Listing and Hearing Review Council (the "Council") may, on its own
 motion, determine to review this Panel decision at any time until
 May 28, 2001.  In the event of such a review, there can be no assurance that
 the Council will affirm the Panel's determination relating to the Company's
 continued listing on the NNM.
     Commenting on the Panel's decision, John E. Ahern, the Company's President
 and Chief Executive Officer, stated that, "We are very pleased that the Panel
 agreed with our assessment of the Company's financial health and its ability
 to meet the NNM's continued listing requirements.  The entire NMT management
 team is committed to continue our operating momentum and to take the steps
 necessary to keep NMT listed on the NNM."
     NMT Medical designs, develops and markets innovative medical devices that
 utilize advanced technologies and are delivered by minimally invasive
 procedures.  The Company's products are designed to offer alternative
 approaches to existing complex treatments, thereby reducing patient trauma,
 shortening procedure, hospitalization and recovery times, and lowering overall
 treatment costs.  The Company's cardiovascular business unit provides the
 interventional cardiologist, interventional radiologist, and vascular surgeon
 with proprietary catheter-based implant technologies that minimize or prevent
 the risk of embolic events.  The cardiovascular business unit also serves the
 pediatric interventional cardiologist with a broad range of cardiac septal
 repair implants delivered with nonsurgical catheter techniques.  The NMT
 neurosciences business unit serves the needs of neurosurgeons with a range of
 implantable and single-use products, including cerebral spinal fluid shunts,
 external drainage products, and the Spetzler(TM) Titanium Aneurysm Clip.
     This press release contains "forward-looking statements" within the
 meaning of the Private Securities Litigation Reform Act of 1995.  Such
 forward-looking statements, including statements regarding the potential of
 the Company's CardioSEAL technology in treating PFOs, involve known and
 unknown risks, uncertainties or other factors which may cause actual results,
 performance or achievements of the Company to be materially different from any
 future results, performance or achievements expressed or implied by such
 forward-looking statements.  Factors that might cause such a difference
 include, but are not limited to, those discussed under the heading "Certain
 Factors That May Affect Future Results" included in the Management's
 Discussion and Analysis of Financial Condition and Results of Operations in
 the Company's Annual Report on Form 10-K for the year ended December 31, 2000
 and subsequent filings with the Securities and Exchange Commission.
     To receive NMT Medical's latest news release and other corporate documents
 via FAX -- at no cost -- please dial 1-800-PRO-INFO.  Enter the Company's
 symbol NMTI.
 
 SOURCE  NMT Medical, Inc.